Peer-reviewed veterinary case report
Kidney function changes in dogs treated for leishmaniosis
By Daza González, M A et al.·Published in Research in veterinary science·2019·Hospital Clí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis.
- Species:
- dog
Plain-English summary
A group of dogs with leishmaniosis, a disease caused by parasites, were treated with meglumine antimoniate and allopurinol to see how it affected their kidney function. Before treatment, most dogs had normal kidney function, but some showed signs of increased or decreased filtration. After the treatment, their kidney function returned to normal, and the amount of protein in their urine decreased, indicating less kidney damage. Overall, the treatment improved their health without harming their kidneys, and all dogs showed better clinical scores.
People also search for: dog leishmaniosis treatment · kidney function in dogs · meglumine antimoniate side effects · dog protein in urine treatment
Abstract
This study examines correlations among serum proteins, clinical score, body weight and kidney function biomarkers after a standard treatment course (meglumine antimoniate plus allopurinol) in twelve Canine leishmaniosis (CanL) patients at the three times points pre treatment, after treatment and after the end of treatment. The laboratory variables measured were those used for the follow-up of sick dogs along with biomarkers of kidney function: glomerular filtration rate (GFR), creatinine (Cr), urea, calcium, inorganic phosphorus, urine specific gravity (USG) and urine protein to creatinine ratio (UPC). Arterial blood pressure (systolic blood pressure, SBP), clinical score (CS) and weight were also monitored over the study period. At Tp0, GFR was within the normal range in most dogs. Hyperfiltration was detected in three patients and hypofiltration in one. In dogs showing hyperfiltration, this factor remained in the non-azotemic range over the whole study period. After treatment normal filtration values were recovered. Meglumine antimoniate did not modify GFR or USG. A significant reduction in UPC was recorded. In all dogs, clinical scores improved. Negative correlation was found between GFR and Cr, UPC and albumin (Alb) and CS and Alb, while positive correlation was detected between UPC and total globulins (GlobT), CS and GlobT, UPC and total solids (TS), SBP and CS and SBP and UPC. Our findings indicate no impacts on kidney function of the treatment of CanL with meglumine antimoniate, as no effects were produced on GFR or USG. Treatment was effective and found to reduce UPC which could suggest improved glomerular injury.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31491669/